Lipids |
|
|
|
LXA4 |
|
|
|
|
|
Virus |
|
|
In vitro and in vivo (macrophages), 5-LO deficient cells
fail to develop M2 macrophage polarization, leading to exuberant
pneumonitis and peri bronchiolitis |
Respiratory sincicial virus (RSV) |
Shirei et al., 2014 |
|
Inhibition of lipoxins production and increased lethality of mice
infected with the H5N1 VN/1203 strain |
IAV |
Cilloniz et al.,
2010 |
|
|
Bacteria |
|
|
Decreased bacterial burden of 5-LO KO mice |
Mycobacterium
tuberculosis |
Bafica et al. 2005 |
|
Increased lung bacterial burden and lethality of infected mice
associated with inhibition of LXA4 production |
Mycobacterium
tuberculosis |
Peres et al., 2007 |
|
LXA4 diminished P. gingivalis aggregation via integrins
activation |
Porphyromonas gingivalis |
Börgeson et al.,
2011 |
|
LXA4 diminished tissue injury and COX-2 levels |
Porphyromonas
gingivalis |
Pouliot et al., 2000 |
|
Inhibition of inflamasome and autophagy inR AW264.7 exposed to
P. gingivalis lipopolysaccharide (PgLPS) |
Porphyromonas
gingivalis |
Zhao et al., 2021 |
|
15-Epi-LXA4 treatment enhanced bacterial clearance |
Escherichia
coli |
Sekheri et al., 2020 |
|
Decrease of IL-6 and TNF when combined with antibiotic treatment |
Escherichia coli |
Ueda et al., 2014 |
|
Inhibition of pro-inflammatory mediators |
Salmonella
typhimurium |
Gewirtz et al., 1998 |
|
Pharmacological inhibition of LXA4 receptor resulted in more pulmonary
edema and increased bacterial loads in the lungs and systemically |
Pneumococcal pneumonia |
Siegel et al., 2021 |
|
Anti-inflammatory effects during cecal ligation and puncture (CLP) in
a rat model |
Cecal ligation and puncture (CLP) |
Walker et al., 2011;
Wu et al., 2014 |
Resolvins (D, E, and T series) |
|
|
|
|
|
Virus |
|
|
Decreased levels of pro-inflammatory cytokines and ACE2 expression
with RvD6 treatment in vitro
|
SARS-CoV-2 |
Pham et al.,
2021 |
|
in vitro, diminished levels of TNF, IL-6, IL-8, CCL2, CCL3 and
CCL4 with RvD1 and RvD2 treatment |
SARS-CoV-2 |
Recchiuti e tal,
2021 |
|
AT-RvD1 ameliorates lung inflammation, without altering viral loads |
H3N2 and Streptococcus pneumoniae co-infection |
Wang et al.,
2017 |
|
Decreased mRNA levels of TNF and IL-8 in pNHBE cells with RvD1
treatment without affecting viral load |
H3N2 |
Guo et al.,
2020 |
|
RvD1 treatment decreased inflammation parameters, although failed to
decrease viral laods in vivo
|
Herpes Simplex Virus (HSV) |
Rajasagi et al., 2017 |
|
RvE1 decreased inflammation and IL-6, IFN-γ and CXCL-1 levels in the
cornea |
HSV-1 |
Rajasagi et al., 2011 |
|
RvE1 restored M2 phenotype of 5-LO macrophages in vitro
|
RSV |
Shirey et al., 2014 |
|
|
Bacteria |
|
|
RvD1 promotes resolution of inflammation in a mouse model of bacterial
keratitis |
Pseudomonas aureoginosa |
Lee et al., 2022; Carion et
al., 2019 |
|
RvD1 and D5 treatment reduced bacterial loads, inflammation and
rescued mice from death |
Citrobacter rodentium |
Diaz et al.,
2017 |
|
RvD2 promotes the resolution of inflammation and bacterial clearance |
Staphylococcus aureus |
Chiang et al., 2015 |
|
RvD2 promotes the resolution of inflammation and bacterial clearance |
Escherichia coli |
Chiang et al., 2015 |
|
RvD4 enhanced efferocytosis in vivo
|
Staphylococcus
aureus |
Winkler et al., 2016 |
|
Decrease in the production of pro inflammatory cytokines via RvD1
treatment in human macrophages |
LPS and Escherichia coli
|
Palmer et al., 2011 |
|
RvD1 and D5 decreased production of inflammatory cytokines and
increased phagocytosis of bacteria by human machrophages |
Escherichia coli |
Chiang et al., 2012 |
|
RvD3 decreased pro-inflammatory cytokines production and accelerates
resolution |
Escherichia coli |
Norris et al.,
2018 |
|
RvD1 treatment decreased inflammation, increased bacterial clearance
and survival of mice |
CLP |
Chen et al., 2014 |
|
RvD1 treatment decreased inflammation in a model of sepsis induced by
D-galactosamine (GalN) |
of sepsis induced by D-galactosamine (GalN) |
Murakami et al., 2011 |
|
RvD1 and D5 decreased production of inflammatory cytokines and
increased phagocytosis of bacteria by human macrophages and neutrophils |
Escherichia coli |
Chiang et al., 2012 |
|
RvD1 treatment reduced bacterial burden and lung inflammation during
infection in mice |
Pseudomonas aureoginosa |
Codagnone et al.,
2018 |
|
AT-RvD1 treatment decreased leukocyte influx and production of pro
inflammatory cytokines and increased bacterial clearance during
Nontypeable Haemophilus influenzae (NTHi) in mice |
Nontypeable
Haemophilus influenzae (NTHi) |
Croasdell et al.,
2016 |
|
Treatment with AT-RvD1 1h post infection enhanced the clearance of
E. coli and Pseudomonas aeruginosa in a murine model of
pneumonia |
Escherichia coli and Pseudomonas aeruginosa
|
Abdulnour et al., 2016 |
|
AT-RvD1 treatment decreased lung inflammation and lung pneumoccocal
load in the lungs |
Streptococcus pneumoniae |
Wang etal,
2017 |
|
17-epi-RvD1 restored human neutrophils apoptosis in vitro and
decreased bacterial load during E. coli infection in the lungs |
Escherichia coli |
Sekheri et al., 2020 |
|
RvD1 treatment decreased lung inflammation and decreased bacterial
burden in cystic fibrosis infected mice |
Pseudomonas aeruginosa |
Isopi et al., 2020 |
|
RvD1 treatment alone or in combination with ceftazidime accelerate the
resolution of inflammation in the lungs |
Pseudomonas aeruginosa |
Gao et al., 2020 |
|
AT-RvD1 treatment attenuated renal inflammation in a model of CLP in
BALB/C mice |
CLP model |
Silva et al., 2021 |
|
RvD1 and RvD2 (individually) treatment diminished bacterial load in
the kidneys in a model of S. aureus infection |
Staphylococcus aureus |
Svahn et al., 2016 |
|
RvD2 treatment decreased bacterial loads in the lungs during P.
aureoginosa infection |
Pseudomonas aeruginosa |
Walker et al.,
2022; Sundarasivarao et al., 2022 |
|
RvE1 treatment decreased inflammation and increased bacterial loads
during E. coli infection |
Escherichia coli |
Seki et al.,
2010 |
|
RvE1 treatment increased antimicrobial activity and decreased
bacterial load against Aggregatibacter actinomycetemcomitans
|
Aggregatibacter actinomycetemcomitans |
Abdullatif et al.,
2022 |
|
decreased inflammation during P. gingivalis infection in mice
and in rabbit treated with RvE1 |
Porphyromonas gingivalis |
Hasturk et al., 2007 |
|
RvE1 attenuated inflammation and reduced bacterial load in a CLP model
and diminished the levels of IL-1B, IL-6 and CCL-2 in LPS stimulated
bone marrow-derived macrophages (BMDMs) |
CLP model |
Chen et al.,
2020 |
|
Resolvins of T series prevented NET formation in vitro and
decreased bacterial load and neutrophil influx during S. aureus
infection in vivo
|
Staphylococcus aureus |
Chiang et al.,
2022 |
Maresins |
|
|
|
|
|
Bacteria |
|
|
Mar-1 decreased bacterial intracellular growth |
Mycobacterium
tuberculosis |
Ruiz et al., 2019 |
|
MCTR3 alone or in combination with MCTR1 decreased lung inflammation and
bacterial burden during
Streptococcus pneumoniae
|
Streptococcus pneumoniae
|
Tavares et al., 2022
|
|
|
Virus |
|
|
Mar-1 decreased inflammation and viral transcripts during RSV
infection |
RSV |
Krishnamoorthy et al., 2023 |
Protectin |
|
|
|
|
|
Bacteria |
|
|
Improved levels of IL-10, TGF-β and IL-4 in the intestinal tract via
PD1 in a model of gut dysbiosis |
Gut dysbiosis |
Ariyoshi et al.,
2021 |
|
PD1 treatment increased uptake of E. coli by human macrophage
and neutrophil |
Escherichia coli |
Hamidzadeh et al., 2022;
Chiang et al., 2012 |
|
PD1 treatment decreased bacterial burden in mice infecte with L.
monocytogenes
|
Listeria monocytogenes |
Bang et al.,
2021 |
|
|
Virus |
|
|
Topic treatment with PD1 during HSV decreased inflammation in rodent
model |
RSV |
Rajasagi et al., 2013 |
|
Intranasal treatment with PD1 and PCTR1 decreased inflammation and
genomic viral load during RSV infection |
RSV |
Walker et al.,
2021 |
|
Decreased viral replication of H1N1 and H5N1 in A549 cells |
IAV |
Morita et al., 2013 |
|
Improved survival rates of mice infected with H1N1 |
IAV |
Morita et
al., 2013 |
α-MSH |
|
|
|
|
|
Bacteria |
|
|
Decrease in the phagocytosis of unopsonized E. coli and
S. aureus by RAW 264.7 |
Escherichia coli and
Staphylococcus aureus
|
Phan and Taylor, 2013 |
|
Downregulation of TLR2 expression induced byS. aureus in human
keratinocytes |
Staphylococcus aureus |
Ryu et al.,
2015 |
|
α-MSH decreased levels of IL-6 induced by LPS in rats |
LPS induced
model |
Huang and Tatro, 1998 |
|
|
Virus |
|
|
α-MSH reduced the production of pro-inflammatory cytokines in the
blood of HIV patients |
HIV |
Catania et al., 1998 |
GILZ |
|
|
|
|
|
Bacteria |
|
|
Increased lung lesion and bacterial burden during bacterial infection
in GILZ KO mice |
Streptococcus pneumoniae |
Souza et al.,
2022 |
|
Enhanced bacterial clearance in CLP model associated with increased
expression of GILZ restricted to macrophages |
CLP model |
Ellouze et
al., 2020 |
|
Up-regulation of GILZ associated with reduced mortality induced by LPS
in mice |
LPS-induced |
Ng et al., 2020 |
AnxA1 |
|
|
|
|
|
Bacteria |
|
|
AnxA1 treatment decreased bacterial burden and inflammation in a model
of meningitis induced by bacteria |
Streptococcus suis |
Ni et
al., 2021 |
|
Ac2-26 treatment decreased bacterial load and inflammation in the
lungs of infected mice via FPR2 receptor |
Streptococcus
pneumoniae |
Machado et al., 2020 |
|
|
Virus |
|
|
Pro-resolutive effects of Ac2-26 treatment during DENV infection |
DENV |
Costa et al., 2022 |
|
Pro-resolutive effects of AC 2-26 treatment during CHIKV infection |
CHIKV |
de Araújo et al., 2022 |
Ang-(1-7) |
|
|
|
|
|
Virus |
|
|
Ang-(1-7) oral administration reduced lethality, promoted resolution
and decreased inflammation associated with Influenza infection |
H1N1 |
Melo et al., 2021 |
|
Mas receptor genetic ablated mice displayed 100% lethality when
infected |
H1N1 |
Melo et al., 2021 |
|
|
Bacteria |
|
|
Ang-(1-7) treatment decreased bacterial load in the lungs and reduced
mortality associated with pneumococcal infection following Influenza A
virus infection |
Streptococcus pneumoniae |
Melo et al.,
2021 |
|
Improved phagocitic capacity of neutrophils from diabetic mice |
Staphylococcus aureus |
Soto et al., 2019 |
|
Ang-(1-7) treatment reduced inflammation associated with infection by
promote M2 phenotype polarization in mice |
CLP model |
Pan et al.,
2021 |
|
Ang-(1-7) treatment reduced inflammation and lethality associated with
infection |
CLP model |
Tsai et al., 2018 |